
Weave automates and accelerates regulatory submission preparation so biopharma teams can produce compliant dossiers faster. The Weave Platform is a cloud-native, AI-powered SaaS that extracts and structures source data, uses AI templates to auto-draft submissions (AutoIND, AutoCT), and validates content against global standards such as FDA eCTD with two-click traceability. It targets biotechs, pharmaceutical companies, CROs, and regulatory consultants and is built to integrate into life-sciences documentation and review workflows. The platform reduces manual regulatory work, improves consistency and compliance, and supports preclinical through approval-stage submissions.

Weave automates and accelerates regulatory submission preparation so biopharma teams can produce compliant dossiers faster. The Weave Platform is a cloud-native, AI-powered SaaS that extracts and structures source data, uses AI templates to auto-draft submissions (AutoIND, AutoCT), and validates content against global standards such as FDA eCTD with two-click traceability. It targets biotechs, pharmaceutical companies, CROs, and regulatory consultants and is built to integrate into life-sciences documentation and review workflows. The platform reduces manual regulatory work, improves consistency and compliance, and supports preclinical through approval-stage submissions.
What they do: AI-native regulatory automation platform that extracts source data and auto-drafts regulatory submissions (e.g., AutoIND, AutoCT)
Target customers: Biotech, pharmaceutical companies, CROs, and regulatory consultants
Founded: 2023
Headquarters / status: San Francisco, CA; private company
Known funding: $10M seed announced May 30, 2024; total funding reported ~42,999,993 USD
Regulatory document preparation and submission management for life-sciences therapies
2023
Biotechnology
10000000
Seed financing announced May 30, 2024 for $10M
42999993
Last funding date listed in company snapshot
“Backed by venture investors including Innovation Endeavors and Magnetic Ventures; additional investors listed in company materials”
| Company |
|---|